Gabelli Funds LLC Has $2.99 Million Stake in Elanco Animal Health Incorporated $ELAN

Gabelli Funds LLC trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 15.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 132,100 shares of the company’s stock after selling 23,900 shares during the period. Gabelli Funds LLC’s holdings in Elanco Animal Health were worth $2,989,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of ELAN. UBS Group AG boosted its position in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the last quarter. Artemis Investment Management LLP bought a new position in Elanco Animal Health in the 4th quarter valued at $55,693,000. Goldman Sachs Group Inc. boosted its position in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Bowen Hanes & Co. Inc. bought a new position in Elanco Animal Health in the 3rd quarter valued at $47,626,000. Finally, Dimensional Fund Advisors LP boosted its position in Elanco Animal Health by 8.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 24,708,676 shares of the company’s stock valued at $497,610,000 after buying an additional 1,962,276 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Rajeev A. Modi purchased 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Jeffrey N. Simmons purchased 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by company insiders.

Elanco Animal Health Stock Up 2.2%

NYSE:ELAN opened at $21.31 on Friday. Elanco Animal Health Incorporated has a 12-month low of $12.40 and a 12-month high of $27.72. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $10.64 billion, a P/E ratio of -42.61, a P/E/G ratio of 2.24 and a beta of 1.69. The stock’s fifty day simple moving average is $23.05 and its 200-day simple moving average is $23.29.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the company earned $0.37 EPS. The firm’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on ELAN. Morgan Stanley increased their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. KeyCorp increased their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research report on Tuesday, March 10th. Finally, Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.